Barinthus Biotherapeutics plc American Depositary Shares (BRNS) is a publicly traded Healthcare sector company. As of May 21, 2026, BRNS trades at $0.69 with a market cap of $26.08M and a P/E ratio of -0.42. BRNS moved +2.41% today. Year to date, BRNS is -5.52%; over the trailing twelve months it is -22.81%. Its 52-week range spans $0.51 to $2.92. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces BRNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Barinthus Biotherapeutics Merger Faces Probe Over 1-for-1 Share Exchange Terms: An investor rights firm is probing Barinthus Biotherapeutics’ merger with Clywedog Therapeutics, under which shareholders receive one share of common stock for each ADS or ordinary share owned, on allegations of fiduciary breaches. The probe aims to secure increased consideration, enhanced disclosures or other relief, potentially affecting merger approval and shareholder value.
| Metric | Value |
|---|---|
| Price | $0.69 |
| Market Cap | $26.08M |
| P/E Ratio | -0.42 |
| EPS | $-1.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.92 |
| 52-Week Low | $0.51 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $506.00K |
| Net Income | $-66.46M |
| Gross Margin | 0.00% |
1 analysts cover BRNS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.